Welcome to Novo Nordisk Pharmaceutical Industries, Inc. (NNPII)
Send to a friendPrint

About Us

Novo Nordisk Pharmaceutical Industries, Inc.  (NNPII)

The insulin production process at NNPII includes product formulation with the mixing of human insulin crystals and chemical stabilizers and ultra-pure water, aseptic filling of glass vials or cartridges, inspection and packaging.  The Clayton site also assembles and packages the FlexPen® disposable insulin device for the US market.

In addition to our production facilities, the site houses administration and laboratories for quality assurance of raw materials, in-process testing, and finished products.

This website aims to provide you with information about NNPII and its parent company Novo Nordisk A/S.  Most sections contain an overview of a particular topic. Look for links for more in-depth information.




Novo Nordisk Pharmaceutical Industries, Inc. (NNPII) Committed to the Triple Bottom Line
NNPII is firmly committed to the integration of sustainable development into the management of our company by focusing on three bottom lines: financial, environmental and social.